Abstract
Abstract
Purpose
This updated systematic review and bivariate meta-analysis aimed to investigate the diagnostic performance of 2-[18F]FDG PET/CT for the detection of recurrent disease in patients with differentiated thyroid cancer (DTC) who have negative 131I whole body scintigraphy and increased antithyroglobulin antibodies (TgAb) levels.
Methods
The current systematic review was carried out following a preset protocol, and the “Preferred Reporting Items for a Systematic Review and Meta-Analysis” served as a guideline for its development and reporting. A comprehensive research of the PubMed/MEDLINE, Embase and Cochrane library databases was conducted until June 2024.
Results
Between 2002 and 2023, 13 studies (608 patients) published on this topic were selected. The pooled sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 2-[18F]FDG PET or PET/CT were 84% (95%CI: 78−87%), 82% (95%CI: 78−86%), 72% (95%CI: 67−76%), 90% (95%CI: 87−93%) and 83% (95%CI: 79%-86%) respectively. The pooled positive and negative likelihood ratios (LR+ and LR − ) and the diagnostic odds ratio (DOR) were 0.180 (95%CI: 0.128–0.253), 3.214 (95%CI: 2.357–4.383), and 17.863 (95%CI: 10.475–30.462), respectively. No statistically significant heterogeneity among the studies was found for all the metrics evaluated (I2 < 50%).
Conclusions
2-[18F]FDG PET/CT demonstrated a good diagnostic performance in patients with DTC and increased TgAb. Although more studies are warranted, the provided evidence-based data should support the integration of 2-[18F]FDG PET/CT in clinical and diagnostic guidelines on DTC patients with increased TgAb.
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)
2. M. Schlumberger, E. Baudin, Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 138, 249–252 (1998)
3. L. Giovanella, Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin. Chem. Lab. Med. 46, 1067–1073 (2008)
4. B.R. Haugen, F. Pacini, C. Reiners, M. schlumberger, P.W. Ladenson, S.I. Sherman et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J. Clin. Endocrinol. Metab. 84, 3877–3885 (1999)
5. C.A. Spencer, M. Takeuchi, M. Kazarosyan, C.C. Wang, R.B. Guttler, P.A. Singer et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 1121–1127 (1998)